NASDAQ:DNAC Social Capital Suvretta Holdings Corp. III (DNAC) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free DNAC Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$9.25▼$10.5050-Day Range$8.41▼$10.0052-Week Range$8.03▼$10.55Volume8,160 shsAverage Volume178,857 shsMarket Capitalization$237.94 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Social Capital Suvretta Holdings Corp. III alerts: Email Address Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024 About Social Capital Suvretta Holdings Corp. IIISocial Capital Suvretta Holdings Corp. III does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company intends to focus on searching for a target business operating in the biotechnology industry and within the organ space sub-sector. Social Capital Suvretta Holdings Corp. III was incorporated in 2021 and is based in Henderson, Nevada.Read More Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024 DNAC Stock News HeadlinesFebruary 10, 2024 | finance.yahoo.comBooz Allen Hamilton Holding Corporation (BAH)December 12, 2023 | markets.businessinsider.comCGrowth Capital Inc. Bolsters Mining Division with Team Expansion and Expert AppointmentsApril 23, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinNovember 16, 2023 | markets.businessinsider.comCGrowth Capital Secures $1 Million in Non-Debt FinancingNovember 1, 2023 | investing.comOji Holdings Corp. (3861)October 24, 2023 | investing.comKuriyama Holdings Corp (3355)July 22, 2023 | wsj.comLeader Capital Holdings Corp.April 5, 2023 | morningstar.comSocial Capital Suvretta Holdings Corp II Class AApril 23, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinJanuary 24, 2023 | seekingalpha.comBREZ Breeze Holdings Acquisition Corp.December 23, 2022 | morningstar.comSocial Capital Suvretta Holdings Corp II Class A DNAB Stock QuoteDecember 8, 2022 | bloomberg.comCredit Suisse Raises $4.3 Billion Capital for RestructuringNovember 28, 2022 | reuters.comFerrotec Holdings CorpJuly 15, 2022 | finance.yahoo.comWinston-Salem regenerative medicine company ProKidney goes public through $600M merger with 'SPAC King'July 13, 2022 | bizjournals.comWinston-Salem regenerative medicine company ProKindey goes public through $600M merger with 'SPAC King'July 12, 2022 | seekingalpha.comProKidney goes public through merger with SPAC Social Capital Suvretta, stock slides 7%July 12, 2022 | finance.yahoo.comRevolutionary Chronic Kidney Disease Therapeutics Company ProKidney to List on the Nasdaq Following Business Combination with Social Capital Suvretta Holdings Corp. IIIJuly 8, 2022 | finance.yahoo.comSocial Capital Suvretta Holdings Corp. III Announces Reconvened Extraordinary General Meeting of ShareholdersJuly 7, 2022 | seekingalpha.comSPAC Social Capital Suvretta III delays shareholder vote on ProKidney mergerJune 23, 2022 | finance.yahoo.comProKidney Corroborates the Mechanism of Action of REACT™ with Cell Marker Analysis in Patients with Diabetic Chronic Kidney DiseaseJune 15, 2022 | finance.yahoo.comProKidney Announces Manufacturing Efficiency Initiatives and Supply Chain Streamlining Expected to Reduce REACT™ Manufacturing CostsJune 7, 2022 | tmcnet.comObserved Safety Profile Supports Bilateral Dosing of ProKidney's REACT™ - 007 UpdateJune 7, 2022 | finance.yahoo.comObserved Safety Profile Supports Bilateral Dosing of ProKidney’s REACT™ – 007 UpdateMay 20, 2022 | finance.yahoo.comProKidney to present at upcoming investor conferencesMay 3, 2022 | benzinga.comProKidney highlights key registrational program elements supporting advancement of REACT®May 3, 2022 | finance.yahoo.comProKidney highlights key registrational program elements supporting advancement of REACT®April 28, 2022 | tmcnet.comProKidney Appoints Libbie Parker McKenzie, MD, FASN as Chief Medical OfficerSee More Headlines Receive DNAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Social Capital Suvretta Holdings Corp. III and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:DNAC CUSIPN/A CIK1850270 WebN/A Phone650-521-9008FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.11 Quick Ratio0.11 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.33) per share Price / Book-28.12Miscellaneous Outstanding Shares25,640,000Free FloatN/AMarket Cap$237.94 million OptionableNot Optionable BetaN/A The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Chamath Palihapitiya (Age 45)CEO & Chairman Mr. Kishan Mehta (Age 36)Pres & Director Dr. James Ryans Ph.D. (Age 46)Chief Financial Officer Key CompetitorsAdverum BiotechnologiesNASDAQ:ADVMCoherus BioSciencesNASDAQ:CHRSSutro BiopharmaNASDAQ:STROFennec PharmaceuticalsNASDAQ:FENCMetagenomiNASDAQ:MGXView All Competitors DNAC Stock Analysis - Frequently Asked Questions When did Social Capital Suvretta Holdings Corp. III IPO? Social Capital Suvretta Holdings Corp. III (DNAC) raised $200 million in an IPO on Wednesday, June 30th 2021. The company issued 20,000,000 shares at a price of $10.00 per share. This page (NASDAQ:DNAC) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryThe Next Nvidia?InvestorPlaceExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersGreat Crypto BullWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Social Capital Suvretta Holdings Corp. III Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
